ANTX - NASDAQ
AN2 Therapeutics, Inc.
$4.28
+3.9%AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotAN2 Therapeutics, Inc. Management Team
Sanjay Chanda
Chief Development Officer
Lucy O. Day
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Compensation
$588,860
Josh Eizen
Chief Legal Officer, Chief Operating Officer & Corporate Secretary
Compensation
$565,988
Stephen David Prior
Chief Strategy Officer
Joseph S. Zakrzewski
Co-Founder & Independent Chairman of the Board
Compensation
$64,577
George Harrison Talbot
Co-Founder & Senior Clinical Advisor
Eric E. Easom
Co-Founder, Chief Executive Officer, President & Chairman of the Board
Compensation
$860,297
Michael R. K. Alley
Co-Founder, Senior Vice President of Research Fellow & Head of Biology
Vince Hernandez
Senior Vice President of Research & Head of Chemistry
AN2 Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $55K worth of ANTX shares, with no buying activity reported.
3 Months
0
0.00
265
1.17K
-1K
-$1K
3-6 Months
0
0.00
49.7K
50.03K
-50K
-$50K
6-9 Months
0
0.00
3.6K
4.08K
-4K
-$4K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Eizen Joshua M
Officer: See Remarks
$28K
Chanda Sanjay
Officer: Chief Development Officer
$9K
Day Lucy
Officer: Chief Financial Officer
$9K
Prior Stephen David
Officer: Chief Strategy Officer
$7K
Williams Sarah Joanne
Officer: Principal Accounting Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $55K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ANTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 10, 2025 | April 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 19, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | June 07, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.